arrow
J

Judith Trotman

university of sydney
H指数:46
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Newly diagnosed and relapsed follicular lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up

新诊断和复发性滤泡性淋巴瘤:EHA 诊断、治疗和随访临床实践指南

2026-10-190
OA
Coronavirus disease 2019 (COVID-19) risk and evolving treatment patterns in follicular lymphoma during the pandemic: Insights from the PETReA trial

2019冠状病毒病(COVID-19)大流行期间滤泡性淋巴瘤的风险及治疗模式的演变:PETReA试验的启示

2026-08-210
PRE
Comparison of immunity-boosting regimens for COVID-19 upon initiation of immunosuppressive therapy (CIRCUIT): study protocol for a randomised, controlled clinical trial

比较免疫增强方案对免疫抑制治疗开始时COVID-19的影响(CIRCUIT):随机对照临床试验研究方案

2026-04-240
PRE
Expanded CD16+CD56+Granzyme B+ NK like CD8+ T cells an off target effect of bruton’s tyrosine kinase inhibitors in Waldenström macroglobulinemia

扩增的CD16+CD56+Granzyme B+ NK样CD8+ T细胞是Bruton’s tyrosine kinase inhibitors在Waldenström macroglobulinemia中的脱靶效应。

2025-10-050
OA
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia

Bruton酪氨酸激酶抑制剂治疗华氏巨球蛋白血症的ASPEN研究第3期中周围神经病变

2025-02-122
OA
Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)

布鲁顿酪氨酸激酶抑制剂(BTKis)剂量中断(DIs)对华氏巨球蛋白血症(WM)患者IgM水平变化及临床结局的长期影响

BLOOD
IF23.1
2024-11-050
PRE
Real World Treatment Outcomes in the First Line Management of Waldenström Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical

真实世界下Waldenström巨球蛋白血症一线治疗管理的结果:来自全球患者衍生数据登记库Whimsical的数据

BLOOD
IF23.1
2024-11-050
PRE
Ibrutinib plus rituximab and mini-CHOP in older patients with newly diagnosed DLBCL: a phase 2 ALLG study

Ibrutinib加利妥昔单抗和mini-CHOP治疗新诊断DLBCL的老年患者: 一项2期ALLG研究

2024-11-010
PRE
Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma
2024-08-170
OAAI
Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies
2024-05-141
OAAI
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia
2024-03-283
OAAI
Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study
2024-03-074
OAAI
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study
2023-11-1510
OAAI